Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
27 results
D3.357 - Revealing an Underlying Inborn Error of Immunity in Pediatric Granulomatous Disease: A Case of STAT1 Loss-of-Function–Associated Mendelian Susceptibility to Mycobacterial Disease after BCG Vaccination
D3.361 - Pulmonary Embolism in a Patient with Hyper IgE (Job) Syndrome Associated with Genetic Thrombophilia: A Rare Case
D3.362 - Ulcerative Colitis Developing in an Immunodeficiency Patient with CD19 Gene Mutation: A Case Report
D3.363 - Systemic Lupus Erythematosus in a Patient with Hyper IgM Syndrome
D3.366 - Experience With Berotralstat In The First Turkish Patients
D3.367 - Clinical and immunological heterogeneity of 22q11.2 deletion syndrome in children from the Republic of Moldova
D3.368 - Selective IgE Deficiency in Children: 10-Year Experience
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis
- D3.519 - Post-COVID-19 Reshaping of Molecular IgE Sensitization Profiles to Seasonal and Indoor Allergens
- D3.520 - Post-COVID Olfactory and Taste Dysfunction in Students at a South African Medical School
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download